Clinical Trials Logo

Clinical Trial Summary

INTRODUCTION: LAM is a rare and lethal disease characterized by progressive cystic lung destruction. Inhibition of mTOR with rapamycin is the current standard of care (SOC), which can slow-down disease. Plasma major histamine metabolite (Methylimidazoleacetic acid [MIAA]) is increased in LAM. Loratadine is a histamine receptor antagonist (HR1), which inhibits LAM cell proliferation. Therefore, a novel phase-II clinical trial for assessing safety and potential benefits of loratadine in LAM has been initiated. METHODS: LORALAM clinical trial, phase-II, double-blind, randomized, placebo controlled, parallel-group, multicentre study initiates recruitment in July 2020. Enrollment plan includes 62 subjects with LAM on treatment with rapamycin ≥3 months, randomized 1:1 to add oral loratadine 10mg/day or placebo, once daily, for 52 weeks. Recruitment will end in June 2021. The primary endpoints are 1) to assess the safety profile of loratadine associated with rapamycin, 2) lung function decline after 52 weeks of treatment. The secondary endpoints are a) quality of life and progression free-survival time, b) changes in the established LAM serum biomarker VEGFD, c) the utility of MIAA for monitoring disease progression and biological treatment effect. ETHICS AND DISSEMINATION: The study will be carried out in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and each ethical committee. This clinical trial contemplates the possibility of increasing the number of centers and including patients from patient support groups (LAM foundation, AELAM)

Clinical Trial Description

Lymphangioleiomyomatosis (LAM) is a rare and lethal lung disease affecting almost exclusively women of childbearing age and characterized by progressive cystic lung destruction. LAM results from germline and somatic loss-of-function mutations in the tuberous sclerosis complex 1 and 2 genes (TSC1/2), and therefore diseased cells show abnormal activation of the mechanistic target of rapamycin (mTOR). Inhibition of mTOR with rapamycin (also known as sirolimus) is the current standard of care. However, this therapy does not fully kill LAM cells, shows variable tolerability and treatment answer. Therefore, sirolimus has slowed-down disease progression but young patients still need lung transplantation despite treatment. In addition, LAM diagnosis and clinical monitoring is also challenging due to the heterogeneity of symptoms and insufficiency of non-invasive tests. Here, guided by comprehensive preclinical data obtained in the context of a Spanish research network for LAM, and with the support of the national Association of LAM patients (AELAM), the investigators propose a phase-II clinical trial for assessing if the tricyclic antihistamine loratadine is effective in slowing the progression of lung disease in LAM. Loratadine is an histamine receptor 1 (HR1) antagonist, widely used for allergic process, that also acts through different intracellular signaling, including Akt/MITF and PKCBII-tyrosine kinase. Recent studies have demonstrated that co-treatment with loratadine sensitize KBV20C resistant cells to vincristine, which improve the onco-therapeutical effect. The primary study objective is to assess the safety profile of loratadine 10 mg/day associated with the current standard treatment (sirolimus) and its potential benefit abrogating the lung function decline after 52 weeks of treatment. The secondary objectives include; a) an assessment of quality of life and progression free-survival time, and, b) to determine the clinical usefulness of the major histamine-derived metabolite methylimidazoleacetic acid (MIAA) for monitoring of disease progression and biological treatment effect. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05190627
Study type Interventional
Source Institut d'Investigació Biomèdica de Bellvitge
Contact Mar Chicote, PM
Phone 0034932607689
Email [email protected]
Status Recruiting
Phase Phase 2
Start date November 1, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT01687179 - Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis Phase 1
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Recruiting NCT03062943 - A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) Phase 2
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Not yet recruiting NCT05087134 - Characterizing LAM With 11C-Choline PET/CT Early Phase 1
Completed NCT02009241 - Pulmonary Rehabilitation in Lymphangioleiomyomatosis N/A
Completed NCT02859194 - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients N/A
Completed NCT01353209 - Trial of Aromatase Inhibition in Lymphangioleiomyomatosis Phase 2
Recruiting NCT03253913 - Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Phase 2
Recruiting NCT02432560 - Safety and Durability of Sirolimus for Treatment of LAM
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Recruiting NCT04577937 - Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis N/A
Completed NCT00005906 - Treatment With Octreotide in Patients With Lymphangioleiomyomatosis Phase 2
Recruiting NCT01799538 - Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis Phase 1/Phase 2
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Completed NCT03131999 - LAM Pilot Study With Imatinib Mesylate Phase 1/Phase 2
Recruiting NCT01484236 - National Lymphangioleiomyomatosis Registry, France
Completed NCT01059318 - A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis Phase 2